Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals reported a Form 144 notice for the proposed sale of
Acumen Pharmaceuticals Chief Legal Officer Derek Meisner reported option exercises and related stock sales. On January 26 and 28, 2026, he exercised a total of 17,756 employee stock options at an exercise price of
On those same dates, he sold 17,756 common shares at weighted average prices of
Acumen Pharmaceuticals, Inc. insider plans to sell additional common stock under Rule 144. A notice covers the proposed sale of 2,671 shares of common stock through Merrill Lynch on 01/28/2026, with an aggregate market value of $8,017.29. The shares relate to an employee stock option exercise on the same date via a broker-assisted cashless transaction.
The filing also lists prior sales of Acumen Pharmaceuticals common stock by Derek Meisner over the past three months, including 4,000 shares for $7,838.00 on 01/05/2026 and 10,898 shares for $21,437.56 on 01/06/2026. Company shares outstanding are stated as 60,573,425, providing context for these transactions.
Acumen Pharmaceuticals insider plans additional stock sale under Rule 144. The notice covers up to 15,085 shares of common stock to be sold through Merrill Lynch on or about 01/27/2026 on the NASDAQ market, with an aggregate market value of $45,262.48. These shares were acquired the same day via a broker-assisted cashless exercise of employee stock options.
The filing also lists prior sales of Acumen Pharmaceuticals common stock during January 2026 by Derek Meisner, including multiple transactions ranging from 1,054 to 36,911 shares. Shares of Acumen Pharmaceuticals outstanding were 60,573,425 at the time referenced, providing context for the size of the planned and recent sales.
Acumen Pharmaceuticals Chief Legal Officer Derek M. Meisner reported three sales of common stock under pre-arranged Rule 10b5-1 trading plans. On January 21, 2026, he sold 2,247 shares at a weighted average price of
Acumen Pharmaceuticals Chief Medical Officer Eric Siemers reported small automatic stock sales to cover taxes related to equity vesting. On January 21, 2026, he sold 2,331 shares of common stock at a weighted average price of $1.8035, and on January 22, 2026, he sold an additional 895 shares at $1.82 per share. The filing explains these were automatic “sell to cover” transactions to satisfy tax withholding obligations from vesting restricted stock units under a Rule 10b5-1 trading plan adopted on September 3, 2024. After these sales, Siemers beneficially owned 255,371 shares of Acumen common stock directly.
Acumen Pharmaceuticals insider activity: CFO & Chief Business Officer Matt Zuga reported small automatic stock sales tied to tax withholding. On 01/21/2026, he sold 2,473 shares of common stock at a weighted average price of $1.8072 per share, followed by a sale of 1,687 shares at $1.86 per share on 01/22/2026. These transactions were executed as “sell to cover” trades to satisfy tax obligations from vesting restricted stock units under a Rule 10b5-1 trading plan adopted on August 30, 2024. After these sales, he directly beneficially owns 304,924 shares of Acumen common stock.
Acumen Pharmaceuticals, Inc. Chief Executive Officer Daniel Joseph O'Connell reported automatic stock sales related to tax withholding. On January 21, 2026, he sold 9,346 shares of common stock at a weighted average price of $1.8112 per share. On January 22, 2026, he sold an additional 2,689 shares at a weighted average price of $1.8838 per share.
According to the footnotes, these transactions were automatic "sell to cover" trades to satisfy tax withholding obligations arising from the vesting of restricted stock units under a Rule 10b5-1 trading plan adopted on June 24, 2024. After these sales, O'Connell beneficially owned 881,275 shares of Acumen common stock directly.
Acumen Pharmaceuticals Chief Operating Officer Barton Russell reported automatic sales of company common stock to cover taxes on vested restricted stock units. On January 21, 2026, he sold 2,315 shares at a weighted average price of $1.806 per share, and on January 22, 2026, he sold an additional 462 shares at $1.84 per share. These transactions were executed as "sell to cover" trades under a Rule 10b5-1 trading plan that he adopted on August 30, 2024, specifically to satisfy tax withholding obligations related to RSU vesting.
Following these transactions, Russell directly held 205,092 shares of Acumen Pharmaceuticals common stock.
Acumen Pharmaceuticals, Inc. (ABOS) shareholder Derek Meisner filed a notice of proposed sale on Form 144 covering 5,633 shares of common stock. The shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.
The planned sale is to be executed through Merrill Lynch on or about 01/23/2026 on the NASDAQ, with an indicated aggregate market value of $10,492.83. The filing notes that 60,573,425 shares of Acumen Pharmaceuticals common stock were outstanding at the time referenced.
The document also lists prior sales by Meisner over the past three months, including multiple common stock transactions in January 2026 with stated gross proceeds for each sale.